Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Arcus Biosciences (RCUS) Gets a Buy Rating from Mizuho Securities
11:56pm, Wednesday, 15'th Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS), with a price target of $22.00. The
Arcus Biosciences (RCUS) Gets a Buy Rating from Mizuho Securities
11:56pm, Wednesday, 15'th Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS – Research
Mizuho Securities Sticks to Its Hold Rating for Incyte (INCY)
04:46pm, Monday, 06'th Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Incyte (INCY), with a price target of $79.00. The company's
Mizuho Securities Sticks to Its Hold Rating for Incyte (INCY)
04:46pm, Monday, 06'th Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Incyte (INCY – Research Report),
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and Collplant Holdings (CLGN)
11:11am, Friday, 03'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities
08:11am, Friday, 03'rd Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Fate Therapeutics (FATE) today and set a price target of $40.00. The company's shares
Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities
08:11am, Friday, 03'rd Apr 2020
Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Fate Therapeutics (
FATE
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Thursday
Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)
02:55am, Friday, 03'rd Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Incyte (INCY) yesterday and set a price target of $79.00. The company's shares closed
Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)
02:55am, Friday, 03'rd Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price
Mizuho Securities Remains a Buy on Merck & Company (MRK)
05:09pm, Thursday, 02'nd Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK) today and set a price target of $100.00. The company's
Mizuho Securities Remains a Buy on Merck & Company (MRK)
05:09pm, Thursday, 02'nd Apr 2020
Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Merck & Company (
MRK
–
Research Report
) today and set a price target of
$100.00
. The company’s shares closed last Thursday at
Mizuho Securities Maintains a Buy Rating on CytomX Therapeutics (CTMX)
02:40am, Tuesday, 31'st Mar 2020
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on CytomX Therapeutics (CTMX), with a price target of
Mizuho Securities Maintains a Buy Rating on CytomX Therapeutics (CTMX)
02:40am, Tuesday, 31'st Mar 2020
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on CytomX Therapeutics (CTMX – Research
Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and OrthoPediatrics (KIDS)
02:47pm, Monday, 30'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN) and OrthoPediatrics (KIDS) with bullish
